There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcturus Therapeutics (ARCT – Research Report) and Alcon (ALC – Research Report) with bullish sentiments.
Arcturus Therapeutics (ARCT)
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Arcturus Therapeutics, with a price target of $45.00. The company’s shares closed last Wednesday at $22.52.
According to TipRanks.com, Zhu is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcturus Therapeutics with a $69.00 average price target, representing a 200.3% upside. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $140.00 price target.
See the top stocks recommended by analysts >>
Alcon (ALC)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Alcon yesterday and set a price target of $89.00. The company’s shares closed last Wednesday at $70.53.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $90.53 average price target, a 27.3% upside from current levels. In a report issued on November 2, UBS also maintained a Buy rating on the stock with a CHF82.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARCT:
- Arcturus Therapeutics reports Q3 EPS (61c), consensus ($1.69)
- Arcturus Therapeutics (ARCT) Q3 Earnings Cheat Sheet
- Acelyrin appoints Patricia Turney as chief technical operations officer
- Arcturus Therapeutics management to meet with William Blair
- Arcturus Therapeutics partner to receive $165M from Japanese government
